BRPI0507661A - método para aumentar a biodisponibilidade de um composto terapeuticamente ativo, e, uso de um composto ativo - Google Patents

método para aumentar a biodisponibilidade de um composto terapeuticamente ativo, e, uso de um composto ativo

Info

Publication number
BRPI0507661A
BRPI0507661A BRPI0507661-7A BRPI0507661A BRPI0507661A BR PI0507661 A BRPI0507661 A BR PI0507661A BR PI0507661 A BRPI0507661 A BR PI0507661A BR PI0507661 A BRPI0507661 A BR PI0507661A
Authority
BR
Brazil
Prior art keywords
active compound
bioavailability
therapeutically active
increasing bioavailability
prevention
Prior art date
Application number
BRPI0507661-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Markku Anttila
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0507661(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of BRPI0507661A publication Critical patent/BRPI0507661A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30Dietetic or nutritional methods, e.g. for losing weight
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
BRPI0507661-7A 2004-02-13 2005-01-14 método para aumentar a biodisponibilidade de um composto terapeuticamente ativo, e, uso de um composto ativo BRPI0507661A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/777,211 US8236861B2 (en) 2004-02-13 2004-02-13 Method for enhancing the bioavailablity of ospemifene
PCT/FI2005/000018 WO2005077350A1 (en) 2004-02-13 2005-01-14 Method for enhancing the bioavailability of ospemifene

Publications (1)

Publication Number Publication Date
BRPI0507661A true BRPI0507661A (pt) 2007-07-17

Family

ID=34837941

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507661-7A BRPI0507661A (pt) 2004-02-13 2005-01-14 método para aumentar a biodisponibilidade de um composto terapeuticamente ativo, e, uso de um composto ativo

Country Status (23)

Country Link
US (5) US8236861B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1713458B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP5577011B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1925847A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE387910T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2005211958B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2015C033I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0507661A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2556089C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1111014T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE602005005165T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1713458T5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2302177T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR15C0041I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUS1500030I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LTC1713458I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU92736I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA06009274A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO337656B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL1713458T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1713458E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2385716C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2005077350A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
PL2275098T3 (pl) 2004-05-04 2012-12-31 Hormos Medical Ltd Nowe doustne preparaty ospemifenu
CN101304738A (zh) * 2005-11-09 2008-11-12 霍尔莫斯医疗有限公司 非培米芬的制剂
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US20070135407A1 (en) * 2005-11-28 2007-06-14 Steiner Mitchell S Serm reduction of lipid profiles
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
ES2389961T3 (es) * 2007-02-14 2012-11-05 Hormos Medical Ltd. Método para la preparación de derivados de trifenilbuteno con valor terapéutico
WO2008099060A2 (en) * 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2014060639A1 (en) 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene
CN103739456A (zh) * 2013-12-03 2014-04-23 镇江圣安医药有限公司 2-(对-((z-4-氯-1,2-二苯基-1-丁烯基)苯氧基)乙醇的新型衍生物及其应用
GR1009542B (el) 2018-04-25 2019-06-07 Φαρματεν Α.Β.Ε.Ε. Καψουλα μαλακης γελης που περιλαμβανει εναν εκλεκτικο ρυθμιστη οιστρογονικων υποδοχεων
SG11202011102TA (en) 2018-05-11 2020-12-30 Xenon Pharmaceuticals Inc Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener
MX2022004209A (es) 2019-10-10 2022-05-03 Xenon Pharmaceuticals Inc Formas cristalinas de estado solido de un modulador selectivo de canales de potasio.
AU2020380961A1 (en) 2019-11-08 2022-05-26 Xenon Pharmaceuticals Inc. Methods of treating depressive disorders
AU2022220675A1 (en) 2021-02-09 2023-09-21 Xenon Pharmaceuticals Inc. Voltage-gated potassium channel opener for use in treating anhedonia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
AU5467699A (en) * 1998-08-07 2000-02-28 Chiron Corporation Substituted isoxazole as estrogen receptor modulators
US6219674B1 (en) 1999-11-24 2001-04-17 Classen Immunotherapies, Inc. System for creating and managing proprietary product data
US6245819B1 (en) 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US6653639B1 (en) * 2000-10-17 2003-11-25 Nikon Corporation Chuck for mounting reticle to a reticle stage
WO2002069254A2 (en) 2001-02-22 2002-09-06 Classen Immunotherapies, Inc. Improved algorithms and methods for products safety
FR2826811B1 (fr) 2001-06-27 2003-11-07 France Telecom Procede d'authentification cryptographique
UA79797C2 (en) 2002-06-06 2007-07-25 Hormos Medical Corp Method for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women
US8236861B2 (en) * 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US20050187302A1 (en) 2004-02-23 2005-08-25 Hormos Medical Corporation Method for treatment or prevention of osteoporosis in individuals with high bone turnover
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US8758821B2 (en) 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
US20060293294A1 (en) 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency
KR100665758B1 (ko) * 2005-09-15 2007-01-09 제일모직주식회사 반사방지성을 갖는 하드마스크 조성물

Also Published As

Publication number Publication date
NO337656B1 (no) 2016-05-23
NO339190B1 (no) 2016-11-14
FR15C0041I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-07-17
AU2005211958A1 (en) 2005-08-25
RU2385716C2 (ru) 2010-04-10
LTC1713458I2 (lt) 2017-06-26
JP2007522190A (ja) 2007-08-09
NO20063960L (no) 2006-11-03
CN1925847A (zh) 2007-03-07
BE2015C033I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2024-08-08
JP6023119B2 (ja) 2016-11-09
CY2015027I1 (el) 2016-04-13
US8772353B2 (en) 2014-07-08
MXPA06009274A (es) 2007-04-16
AU2005211958B2 (en) 2010-11-25
EP1713458B1 (en) 2008-03-05
CA2556089A1 (en) 2005-08-25
US20130324614A1 (en) 2013-12-05
PL1713458T3 (pl) 2008-08-29
LU92736I2 (fr) 2015-08-10
US8470890B2 (en) 2013-06-25
US9241915B2 (en) 2016-01-26
DE602005005165T2 (de) 2009-04-30
CY1111014T1 (el) 2015-06-11
US20140303259A1 (en) 2014-10-09
CY2015027I2 (el) 2016-04-13
DK1713458T3 (da) 2008-07-07
ATE387910T1 (de) 2008-03-15
HUS1500030I1 (hu) 2015-08-28
US20050182143A1 (en) 2005-08-18
US20160101065A1 (en) 2016-04-14
EP1713458A1 (en) 2006-10-25
FR15C0041I2 (fr) 2015-11-13
ES2302177T3 (es) 2008-07-01
LTPA2015023I1 (lt) 2015-08-25
JP5577011B2 (ja) 2014-08-20
PT1713458E (pt) 2008-05-07
WO2005077350A1 (en) 2005-08-25
RU2006132719A (ru) 2008-03-20
US9855224B2 (en) 2018-01-02
US20120270952A1 (en) 2012-10-25
NO20151603L (no) 2006-11-03
US8236861B2 (en) 2012-08-07
JP2014141533A (ja) 2014-08-07
CA2556089C (en) 2013-04-02
DE602005005165D1 (de) 2008-04-17
DK1713458T5 (da) 2008-09-29

Similar Documents

Publication Publication Date Title
BRPI0507661A (pt) método para aumentar a biodisponibilidade de um composto terapeuticamente ativo, e, uso de um composto ativo
SG10201909122QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
BRPI0606736A2 (pt) combinação de compostos e esteróides de metilxantina para tratar doenças respiratórias crÈnicas
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
NO341573B1 (no) Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen
UY28860A1 (es) Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos
WO2007128802A3 (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
MY153852A (en) Galenic formulations of organic compounds
DK1305014T3 (da) Anvendelse af (deaminohydroxy)toremifen til behandling af vaginal törhed eller seksuel dysfunktion hos kvinder under eller efter menopausen
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
JP2008533079A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA201170405A1 (ru) Монотерпены для лечения заболеваний дыхательных путей, в частности, бронхолегочных заболеваний
WO2008073466A3 (en) Alpha b-crystallin as a therapy for inflammation
ECSP11010941A (es) Composición farmacéutica para el uso en el tratamiento de infecciones de transmisión sexual
IL164528A (en) Method for inhibition of atrophy or for treatment or prevention of atrophy related symptoms in women
WO2010041889A3 (en) Pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease
MX2010004423A (es) Una forma amorfa de un compuesto antiinflamatorio.
WO2010047559A3 (ko) 방출성이 제어된 약제학적 제제
EA201592159A1 (ru) Применение тиазолопиримидинона для лечения воспалительного заболевания кишечника
RU2004133450A (ru) Способ лечения бронхиальной астмы, сочетанной с эрозивно-язвенными поражениями гастродуоденальной зоны
AR064602A1 (es) Nebulizador anticonceptivo oral
UA57768U (ru) Способ лечения ишемической болезни сердца c артериальной гипертензией ha фоне дислипидемии c сердечной недостаточностью у больных пожилого возраста
AR063816A1 (es) Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion
ATE442848T1 (de) Isoxazolsäure-derivat zur linderung neuropathischer schmerzen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]